logo
We finally may be able to rid the world of mosquitoes. But should we?

We finally may be able to rid the world of mosquitoes. But should we?

Yahoo04-06-2025
They buzz, they bite, and they cause some of the deadliest diseases known to humanity. Mosquitoes are perhaps the planet's most universally reviled animals.
If we could zap them off the face of the Earth, should we?
Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post.
The question is no longer hypothetical. In recent years, scientists have devised powerful genetic tools that may be able to eradicate mosquitoes and other pests once and for all.
Now, some doctors and scientists say it is time to take the extraordinary step of unleashing gene editing to suppress mosquitoes and avoid human suffering from malaria, dengue, West Nile virus and other serious diseases.
'There are so many lives at stake with malaria that we want to make sure that this technology could be used in the near future,' said Alekos Simoni, a molecular biologist with Target Malaria, a project aiming to target vector mosquitoes in sub-Saharan Africa.
Yet the development of this technology also raises a profound ethical question: When, if ever, is it okay to intentionally drive a species out of existence?
Even the famed naturalist E.O. Wilson once said: 'I would gladly throw the switch and be the executioner myself' for malaria-carrying mosquitoes.
But some researchers and ethicists warn it may be too dangerous to tinker with the underpinnings of life itself. Even irritating, itty-bitty mosquitoes, they say, may have enough inherent value to keep around.
- - -
How to exterminate mosquitoes
Target Malaria is one of the most ambitious mosquito suppression efforts in the works. Simoni and his colleagues are seeking to diminish populations of mosquitoes in the Anopheles gambiae complex that are responsible for spreading the deadly disease.
In their labs, the scientists have introduced a gene mutation that causes female mosquito offspring to hatch without functional ovaries, rendering them infertile. Male mosquito offspring can carry the gene but remain physically unaffected.
The concept is that when female mosquitoes inherit the gene from both their mother and father, they will go on to die without producing offspring. Meanwhile, when males and females carrying just one copy of the gene mate with wild mosquitoes, they will spread the gene further until no fertile females are left - and the population crashes.
Simoni said he hopes Target Malaria can move beyond the lab and deploy some of the genetically modified mosquitoes in their natural habitats within the next five years. The nonprofit research consortium gets its core funding from the Gates Foundation, backed by Microsoft co-founder Bill Gates, and Open Philanthropy, backed by Facebook co-founder Dustin Moskovitz and his wife, Cari Tuna.
'We believe that this technology can really be transformative,' Simoni said.
At the heart of Target Malaria's work is a powerful genetic tool called a gene drive.
Under the normal rules of inheritance, a parent has a 50-50 chance of passing a particular gene on to an offspring. But by adding special genetic machinery - dubbed a gene drive - to segments of DNA, scientists can rig the coin flip and ensure a gene is included in an animal's eggs and sperm, nearly guaranteeing it will be passed along.
Over successive generations, gene drives can cause a trait to spread across an entire species's population, even if that gene doesn't benefit the organism.
In that way, gene drives do something remarkable: They allow humans to override Charles Darwin's rules for natural selection, which normally prods populations of plants and animals to adapt to their environment over time.
'Technology is presenting new options to us,' said Christopher Preston, a University of Montana environmental philosopher. 'We might've been able to make a species go extinct 150 years ago by harpooning it too much or shooting it out of the sky. But today, we have different options, and extinction could be completed or could be started in a lab.'
- - -
How far should we go in eradicating mosquitoes?
When so many wildlife conservationists are trying to save plants and animals from disappearing, the mosquito is one of the few creatures that people argue is actually worthy of extinction. Forget about tigers or bears; it's the tiny mosquito that is the deadliest animal on Earth.
The human misery caused by malaria is undeniable. Nearly 600,000 people died of the disease in 2023, according to the World Health Organization, with the majority of cases in Africa.
On the continent, the death toll is akin to 'crashing two Boeing 747s into Kilimanjaro' every day, said Paul Ndebele, a bioethicist at George Washington University.
For gene-drive advocates, making the case for releasing genetically modified mosquitoes in nations such as Burkina Faso or Uganda is straightforward.
'This is not a difficult audience, because these are people that are living in an area where children are dying,' said Krystal Birungi, an entomologist for Target Malaria in Uganda, though she added that she sometimes has to fight misinformation, such as the false idea that bites from genetically modified mosquitoes can make people sterile.
But recently, the Hastings Center for Bioethics, a research institute in New York, and Arizona State University brought together a group of bioethicists to discuss the potential pitfalls of intentionally trying to drive a species to extinction. In a policy paper published in the journal Science last month, the group concluded that 'deliberate full extinction might occasionally be acceptable, but only extremely rarely.'
A compelling candidate for total eradication, according to the bioethicists, is the New World screwworm. This parasitic fly, which lays eggs in wounds and eats the flesh of both humans and livestock, appears to play little role in ecosystems. Infections are difficult to treat and can lead to slow and painful deaths.
Yet it may be too risky, they say, to use gene drives on invasive rodents on remote Pacific islands where they decimate native birds, given the nonzero chance of a gene-edited rat or mouse jumping ship to the mainland and spreading across a continent.
'Even at a microbial level, it became plain in our conversations, we are not in favor of remaking the world to suit human desires,' said Gregory Kaebnick, a senior research scholar at the institute.
It's unclear how important malaria-carrying mosquitoes are to broader ecosystems. Little research has been done to figure out whether frogs or other animals that eat the insects would be able to find their meals elsewhere. Scientists are hotly debating whether a broader 'insect apocalypse' is underway in many parts of the world, which may imperil other creatures that depend on them for food and pollination.
'The eradication of the mosquito through a genetic technology would have the potential to create global eradication in a way that just felt a little risky,' said Preston, who contributed with Ndebele to the discussion published in Science.
Instead, the authors said, geneticists should be able to use gene editing, vaccines and other tools to target not the mosquito itself, but the single-celled Plasmodium parasite that is responsible for malaria. That invisible microorganism - which a mosquito transfers from its saliva to a person's blood when it bites - is the real culprit.
'You can get rid of malaria without actually getting rid of the mosquito,' Kaebnick said. He added that, at a time when the Trump administration talks cavalierly about animals going extinct, intentional extinction should be an option for only 'particularly horrific species.'
But Ndebele, who is from Zimbabwe, noted that most of the people opposed to the elimination of the mosquitoes 'are not based in Africa.'
Ndebele has intimate experience with malaria; he once had to rush his sick son to a hospital after the disease manifested as a hallucinatory episode.
'We're just in panic mode,' he recalled. 'You can just imagine - we're not sure what's happening with this young guy.'
Still, Ndebele and his colleagues expressed caution about using gene-drive technology.
Even if people were to agree to rid the globe of every mosquito - not just Anopheles gambiae but also ones that transmit other diseases or merely bite and irritate - it would be a 'herculean undertaking,' according to Kaebnick.
There are more than 3,500 known species, each potentially requiring its own specially designed gene drive. And there is no guarantee a gene drive would wipe out a population as intended.
Simoni, the gene-drive researcher, agreed that there are limits to what the technology can do. His team's modeling suggests it would suppress malaria-carrying mosquitoes only locally without outright eliminating them.
Mosquitoes have been 'around for hundreds of millions of years,' he said. 'It's a very difficult species to eliminate.'
Related Content
Some advice from LGBTQ elders as WorldPride kicks off amid fears
Black Democrats fume over 2024 while 'searching for a leader' in 2028
Joy, tension collide as WorldPride arrives in Trump's Washington
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

White House backs away from IVF mandate despite Trump's campaign pledge, Washington Post
White House backs away from IVF mandate despite Trump's campaign pledge, Washington Post

USA Today

time7 hours ago

  • USA Today

White House backs away from IVF mandate despite Trump's campaign pledge, Washington Post

WASHINGTON − The White House has no current plans to mandate insurance coverage for in vitro fertilization, despite President Donald Trump's campaign promise to expand access to fertility treatments, The Washington Post reported on Saturday. Trump signed an executive order earlier this year directing the government to expand access to IVF and reduce the costs of the popular fertility treatment. More: Some workers are job hopping for fertility benefits. Employers are trying to keep up. White House officials say expanding IVF access remains a priority, but legal constraints prevent mandating coverage without Congressional approval, and no bill is currently planned, the Post reported. Officials did not immediately respond to a request for comment by USA TODAY. Contributing: Francesca Chambers

Canada has its 1st case of West Nile this year. Here's what to know about the virus
Canada has its 1st case of West Nile this year. Here's what to know about the virus

Hamilton Spectator

timea day ago

  • Hamilton Spectator

Canada has its 1st case of West Nile this year. Here's what to know about the virus

TORONTO - Confirmation of the first human case of West Nile virus acquired in Canada this year arrived just in time for the August long weekend. The Public Health Agency of Canada said Thursday that an adult in Toronto with no travel history has been infected with the mosquito-borne virus. There had previously been two people with West Nile virus in Canada, but they were infected while travelling outside the country. Here's what you need to know about West Nile virus as you head outdoors this weekend. WHAT IS WEST NILE VIRUS? The first human case of West Nile virus appeared in Canada in 2002. The virus was originally identified in the West Nile region of Uganda, said Dr. Isaac Bogoch, an infectious diseases specialist at the University Health Network in Toronto, but was carried to many places around the world by migratory birds. When mosquitoes bite infected birds, they in turn become infected and then can pass on the virus to humans and other animals when they bite them. The type of mosquitoes that transmit West Nile virus usually bite around dusk and at night, Bogoch said. Human infections usually occur in mid to late summer, petering out as the temperature cools down. The Public Health Agency of Canada says humans don't spread the virus to other humans, except for very rare cases including blood transfusions, organ or tissue transplants, mother-to-child transmission during pregnancy or breastfeeding. WHAT ARE THE SYMPTOMS? 'The vast majority of people who are bitten by a mosquito harbouring West Nile virus will have no symptoms whatsoever,' said Bogoch. For the 20 to 30 per cent of people who get sick, most will have a few days of symptoms that resolve on their own. Symptoms usually begin between two and 14 days after the mosquito bite. They can include fever, muscle aches, headaches, fatigue, nausea, vomiting, skin rash, swollen lymph glands and a stiff neck. The concerning part of West Nile virus is that up to two per cent of people infected will get neuroinvasive disease, including encephalitis or meningitis, Bogoch said. Encephalitis is inflammation of the brain and meningitis is inflammation of the area around the brain and spinal cord. In 'very rare' cases, people can also develop paralysis, he said. Although anyone can get these severe West Nile virus infections, they tend to happen more in older adults, Bogoch said. HOW IS WEST NILE VIRUS TREATED? There is no antiviral medication to treat West Nile virus. Most people won't need medical attention and can manage aches and pains with over-the-counter acetaminophen, rest and fluids. For the rare cases of neuroinvasive diseases, hospitals provide supportive care, including fluids and electrolytes, and provide rehabilitation if needed. IS THERE A VACCINE FOR WEST NILE VIRUS? There is no vaccine for West Nile virus. HOW CAN I PREVENT WEST NILE VIRUS? The best way to prevent West Nile virus is to avoid being bitten by a mosquito in the first place. Using insect repellent is 'very effective,' Bogoch said. Both Bogoch and the Public Health Agency of Canada recommend using bug sprays and lotions containing the chemicals DEET or Icaridine. Health Canada says those products should not be used on infants under six months old and parents can use mosquito nets over cribs or strollers when babies are outside instead. Wearing long sleeves and long pants, socks and a hat can also protect against mosquito bites. People can also wear mosquito nets over their hats. Choose light-coloured clothing, because mosquitoes are attracted to dark colours. Making sure all open windows have screens to keep mosquitoes and other bugs out is important. Getting rid of any standing water around your home or cottage also helps because that's where mosquitoes lay eggs. Drain buckets, planters, old tires, pool covers, wading pools and other objects where water accumulates. HOW COMMON IS IT? The number of reported cases annually varies greatly since PHAC started tracking domestic infections in 2003, ranging from a handful of cases per year to a peak of 2,401 cases in 2007. In 2024, there were 166 reported cases, according to PHAC's preliminary data. 'For most Canadians, the risk of getting infected is low because relatively few mosquitoes in Canada are infected with West Nile virus,' said Mark Johnson, a spokesperson for PHAC, in an email Friday. This report by The Canadian Press was first published Aug. 2, 2025. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

Medicare Update: Trump Admin Launching Pilot Program to Cover Ozempic
Medicare Update: Trump Admin Launching Pilot Program to Cover Ozempic

Newsweek

time2 days ago

  • Newsweek

Medicare Update: Trump Admin Launching Pilot Program to Cover Ozempic

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Trump administration is preparing a five-year pilot program that would allow Medicare and Medicaid to cover some of the most in-demand weight-loss drugs, a move that could transform obesity treatment for millions of Americans. The plan, which includes medications such as Ozempic, Wegovy, Mounjaro and Zepbound, represents a reversal in federal policy and signals a broader willingness to use public insurance to address the nation's obesity epidemic. Why It Matters The drugs, known as GLP-1 receptor agonists, were initially developed to treat Type 2 diabetes but have become a cultural phenomenon for their ability to suppress appetite and help patients lose as much as 20 percent of their body weight in clinical trials. The pilot builds on a proposal introduced in the final months of the Biden administration but shelved earlier this year when officials under President Donald Trump announced Medicare and Medicaid would not cover weight-loss medications. What To Know According to documents obtained by The Washington Post, the program would allow state Medicaid programs and Medicare Part D plans to voluntarily cover GLP-1 drugs for weight management. The initiative is scheduled to begin in April 2026 for Medicaid and January 2027 for Medicare and will be administered through the Center for Medicare and Medicaid Innovation, which tests new payment models designed to reduce costs and improve care. Chiquita Brooks-LaSure, who led the Centers for Medicare and Medicaid Services under former President Joe Biden, told the Post the experiment would be a "game changer" if it expands access to obesity treatments. "Increased coverage of anti-obesity medications in Medicare and Medicaid was a priority during my tenure because scientists and clinicians increasingly believe obesity is a serious health condition that should be treated accordingly," she said. A pharmacy owner displays an Ozempic package in Pristina, Kosovo, on March 27. A pharmacy owner displays an Ozempic package in Pristina, Kosovo, on March 27. Photo by ARMEND NIMANI/AFP via Getty Images The program faces a major hurdle: price. GLP-1 drugs typically cost from $5,000 to $7,000 a year, raising questions about whether widespread coverage is sustainable. "The short-term cost is still huge," Dr. Cynthia Cox, vice president at KFF (formerly Kaiser Family Foundation), told Newsweek. "$1,000 a month per person is a massive outlay." A KFF analysis found that Ozempic's U.S. list price is $936 a month—more than five times the cost in Japan, where it sells for $169. Wegovy, which contains the same active ingredient, costs roughly $1,349 a month in the U.S., compared to $328 in Germany. At the moment, 13 state Medicaid programs cover GLP-1 drugs for obesity. Medicare limits coverage to patients with related conditions such as diabetes or heart disease. With about 70 million people enrolled in Medicaid and 65 million in Medicare, even partial expansion could affect a significant share of the population. Ethicists warn of the potential economic fallout. "These drugs help over 50 percent of people lose up to 25 percent of their body weight," said Dr. Robert Klitzman, a Columbia University bioethicist, in an interview with Newsweek. "But they cost around $12,000 a year. If two-thirds of Americans needed them, it would bankrupt the health care system." Despite the financial concerns, GLP-1 medications are generating enthusiasm among doctors for their ability to improve multiple health markers beyond weight loss. Clinical trials show they can reduce blood sugar, lower blood pressure and improve cardiovascular outcomes. "Ozempic and other GLP-1 drugs are changing how we approach obesity, both in the doctor's office and for society in general," Dr. Raj Dasgupta, chief medical adviser for Garage Gym Reviews, told Newsweek. "They're helping shift the conversation from 'this is a personal failure' to 'this is a medical condition that deserves real treatment.'" The Congressional Budget Office estimates that adding obesity coverage could cost Medicare $35 billion from 2026 to 2034. What People Are Saying A spokesperson for Novo Nordisk, which manufactures Ozempic and Wegovy, told The Washington Post: "We believe that comprehensive coverage through government and commercial insurance plans is critical to affordable health care and treatment options." Klitzman also said in the interview with Newsweek: "Insurance doesn't always cover it, especially for people who don't have diabetes or heart disease. Initially, the drugs were approved for diabetes-related obesity, but doctors have been prescribing them to people who are just overweight, without those conditions." What Happens Next With more than 100 million U.S. adults classified as obese and 22 million considered severely obese, according to the Centers for Disease Control and Prevention, the program's potential impact is vast. The proposal is not final and could undergo a formal public comment period before implementation.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store